Literature DB >> 14577918

Biodistribution of oncolytic measles virus after intraperitoneal administration into Ifnar-CD46Ge transgenic mice.

Kah-Whye Peng1, Marie Frenzke, Rae Myers, Diane Soeffker, Mary Harvey, Suzanne Greiner, Evanthia Galanis, Roberto Cattaneo, Mark J Federspiel, Stephen J Russell.   

Abstract

In support of a proposed phase I clinical trial, we studied the biodistribution of virus-infected cells after intraperitoneal administration of oncolytic measles viruses to alpha/beta interferon-defective mice expressing human CD46 with human-like tissue specificity. Various marker genes were employed, and green fluorescent protein proved to be most informative. Mesothelium and ovarian surface epithelium were remarkably resistant to infection, but infected peritoneal macrophages were present in abundance both in peritoneal lavage fluid and in the greater omentum, where they were heavily concentrated in "milky spots". Infected macrophages were also identified outside the peritoneal cavity, along the peritoneal fluid drainage pathway and in the spleen. Thus, diaphragmatic stomata, thoracic lymphatic vessels, and parathymic lymph nodes contained numerous measles-infected cells, as did the marginal zones of the white pulp of the spleen. Splenic marginal zone macrophages were the predominant targets of infection after intravenous administration of oncolytic measles viruses. When measles-infected peritoneal macrophages were adoptively transferred, they did not migrate beyond the confines of the peritoneal cavity, suggesting that, after intraperitoneal virus administration, the positive cells in thoracic lymphatics, parathymic lymph nodes, and spleen are nonmigratory cells transduced in situ by viral particles that have exited from the peritoneal cavity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14577918     DOI: 10.1089/104303403322495070

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  25 in total

1.  Immunoglobulin g antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response.

Authors:  Ianko D Iankov; Manoj Pandey; Mary Harvey; Guy E Griesmann; Mark J Federspiel; Stephen J Russell
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  Engineering oncolytic measles virus to circumvent the intracellular innate immune response.

Authors:  Iana Haralambieva; Ianko Iankov; Kosei Hasegawa; Mary Harvey; Stephen J Russell; Kah-Whye Peng
Journal:  Mol Ther       Date:  2007-01-16       Impact factor: 11.454

Review 3.  Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics.

Authors:  Christian K Pfaller; Roberto Cattaneo; Matthias J Schnell
Journal:  Virology       Date:  2015-02-18       Impact factor: 3.616

Review 4.  Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects.

Authors:  Pavlos Msaouel; Mateusz Opyrchal; Angela Dispenzieri; Kah Whye Peng; Mark J Federspiel; Stephen J Russell; Evanthia Galanis
Journal:  Curr Cancer Drug Targets       Date:  2018       Impact factor: 3.428

Review 5.  Measles virus.

Authors:  Hussein Y Naim
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

Review 6.  Oncolytic measles virus strains as novel anticancer agents.

Authors:  Pavlos Msaouel; Mateusz Opyrchal; Evidio Domingo Musibay; Evanthia Galanis
Journal:  Expert Opin Biol Ther       Date:  2013-01-06       Impact factor: 4.388

Review 7.  Vaccine immunogenetics: bedside to bench to population.

Authors:  Gregory A Poland; Inna G Ovsyannikova; Robert M Jacobson
Journal:  Vaccine       Date:  2008-07-01       Impact factor: 3.641

Review 8.  Measles virus for cancer therapy.

Authors:  S J Russell; K W Peng
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

9.  Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide.

Authors:  R M Myers; S M Greiner; M E Harvey; G Griesmann; M J Kuffel; S A Buhrow; J M Reid; M Federspiel; M M Ames; D Dingli; K Schweikart; A Welch; A Dispenzieri; K-W Peng; S J Russell
Journal:  Clin Pharmacol Ther       Date:  2007-10-31       Impact factor: 6.875

10.  Engineered measles virus as a novel oncolytic therapy against prostate cancer.

Authors:  Pavlos Msaouel; Ianko D Iankov; Cory Allen; John C Morris; Veronika von Messling; Roberto Cattaneo; Michael Koutsilieris; Stephen J Russell; Evanthia Galanis
Journal:  Prostate       Date:  2009-01-01       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.